Molecular diagnostics of acute intermittent porphyria

Expert Review of Molecular Diagnostics

Volumn 4, Issue 2, 2004, Pages 243-249

  Kauppinen, Raili ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Diagnosis; Mutation; Porphyria

Indexed keywords

PORPHOBILINOGEN;

ACUTE INTERMITTENT PORPHYRIA; AUTOSOMAL DOMINANT INHERITANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA DETERMINATION; GENE INTERACTION; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; MUTATIONAL ANALYSIS; PATHOGENESIS; PHARMACOGENETICS; PREVALENCE; PROGNOSIS; REVIEW; URINALYSIS;

GENETIC SCREENING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PORPHOBILINOGEN; PORPHYRIA, ACUTE INTERMITTENT; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 1542268290     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.2.243     Document Type: Review

References (55)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet A, Sly WS, Valle D (Eds), McGraw-Hill, NY, USA, 2991-3062 (2001).
2. Meyer UA, Strand LJ, Doss M, Rees AC, Marver HS. Intermittent acute porphyria - demonstration of a genetic defect in porphobilinogen metabolism. N. Engl. J. Med. 286, 1277-1282 (1972).
3. Grandchamp B, Picat C, Kauppinen R et al. Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase. Eur. J. Clin. Invest. 19, 415-148 (1989).
4. Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch. Dermatol. 116, 543-547 (1980).
5. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin. Chem. 48, 1891-1900 (2002). Large series of acute intermittent porphyria (AIP) patients analyzed biochemically and using mutation analysis.
6. Andersson C, Thunell S, Floderus Y et al. Diagnosis of acute intermittent porphyria in Northern Sweden: an evaluation of mutation analysis and biochemical methods. J. Int. Med. 237, 301-308 (1995).
7. Goldberg A. Acute intermittent porphyria: a study of 50 cases. Q. J. Med. 28, 183-209 (1959).
8. Stein JA, Tschudy DP. Acute intermittent porphyria: a clinical and biochemical study of 46 patients. Medicine 49, 1-16 (1970).
9. Mustajoki P, Koskelo P. Hereditary hepatic porphyrias in Finland. Acta Med. Scand. 200, 171-178 (1976).
10. Crimlisk HL. The little imitator: porphyria: a neuropsychiatric disorder. J. Neurol. Neurosurg. Psychiatry 62, 319-328 (1997). Good clinical review.
11. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors and associated diseases. Medicine 71, 1-13 (1992). One of the few current clinical articles on AIP.
12. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin. Liver Dis. 18, 43-52 (1998). Good description of potential pathophysiology of AIP.
13. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch. Int. Med. 153, 2004-2008 (1993). Well-documented series of AIP patients treated with heme arginate.
14. Jeans JB, Savik K, Gross CR et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J. Med. Genet. 65, 269-273 (1996).
15. Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J. Intern. Med. 236, 169-175 (1994).
16. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J. Intern. Med. 240, 195-201 (1996).
17. Bradbury M. The Concept of a Blood-Brain Barrier. John Wiley & Sons Ltd., Chichester, UK (1979).
18. Yen PS, Chen CJ, Lui CC, Wai YY, Wan YL. Diffusion-weighted magnetic resonance imaging of porphyric encephalopathy: a case report. Eur. Neurol. 48, 119-121 (2002).
19. Bonkowsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin. Liver Dis. 18, 57-65 (1998).
20. Schirmer M, Calamia KT, Wenger M, Klauser A, Salvarani C, Moncayo R. 18F-fluorodeoxyglucose-positron emission tomography: a new explorative perspective. Exp. Gerontol. 38, 463-470 (2003).
21. Heils A, Mossner R, Lesch K. The human serotonin transporter gene polymorphism: basic research and clinical implications. J. Neural. Transm. 104, 1005-1014 (1997).
22. Jover R, Hoffmann F, Scheffler-Koch V, Lindberg RL. Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur. J. Biochem. 267, 7128-7137 (2000).
23. Lindberg RL, Martini R, Baumgatner M et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J. Clin. Invest. 103, 1127-1134 (1999).
24. Beukeveld GJ, Wolthers BG, Nordmann Y, Deybach JC, Grandchamp B, Wadman SK. A retrospective study of a patient with homozygous form of acute intermittent porphyria. J. Inherit. Metab. Dis. 13, 673-683 (1990).
25. Halapi E, Hakonarson H. Advances in development of genetic markers for the diagnosis of disease and drug response. Expert Rev. Mol. Diagn. 2, 411-21 (2002).
26. Mustajoki P, Mustajoki S, Rautio A, Arvela P, Pelkonen O. Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and healthy men. Clin. Pharmacol. Ther. 56, 9-13 (1994).
27. Namba H, Narahara K, Tsuji K, Yokoyama Y, Seino Y. Assignment of human porphobilinogen deaminase to 11q24.1-q24.2 by in situ hybridization and gene dosage studies. Cytogenet. Cell Genet. 57, 105-108 (1991).
28. Raich N, Romeo PH, Dubart A, Beaupain D, Cohen-Solal M, Goosens M. Molecular cloning and complete primary sequence of human erythrocyte PBG deaminase. Nucleic Acids Res. 14, 5955-5968 (1986). First article related to the characterization of the porphobilinogen deaminase (PBGD) cDNA.
29. Yoo HW, Warner CA, Chen CH, Desnick RJ. Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene. Genomics 15, 21-29 (1993).
30. Grandchamp B, de Verneuil H, Beaumont C, Chretien S, Walter O, Nordmann Y. Tissue-specific expression of porphobilinogen deaminase: two isoenzymes from a single gene. Eur. J. Biochem 162, 105-110 (1987). First article describing tissue specificity of PBGD.
31. Gubin AN, Miller JL. Human erythroid porphobilinogen deaminase exists in two splice variants. Blood 97, 815-817 (2002).
32. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann. Int. Med. 83, 851-864 (1975).
33. Mustajoki P, Kauppinen R, Lannfelt L, Lilius L, Koistinen J. Frequency of low erythrocyte porphobilinogen deaminase activity in Finland. J. Int. Med. 231, 389-395 (1992).
34. Nordmann Y, Puy H, Da Silva V et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J. Int. Med. 242, 213-217 (1997).
35. Andersson C. Acute Intermittent Porphyria in Northern Sweden. A Population-Based Study. Departments of Family Medicine and Medicine, University of Umeå, Sweden, 102 (1997).
36. Schneider-Yin X, Hergersberg M, Goldgar DE et al. Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients. Hum. Hered. 54, 69-81 (2002).
37. De Siervi A, Rossetti MV, Parera VE et al. Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation. Am. J. Med. Genet. 86, 366-375 (1999).
38. Mullis KB, Faloona F. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. In: Methods in Enzymology. Wu R (Ed.), Academic Press, NY, USA, 335-350 (1987).
39. Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 20, 1350-1354 (1985).
40. Minarik M, Minarikova L, Bjorheim J, Ekstrom PO. Cycling gradient capillary electrophoresis: a low-cost tool for high-throughput analysis of genetic variations. Electrophoresis 24, 1716-1722 (2003).
41. Kauppinen R, Mustajoki S, Pihlaja H, Peltonen L, Mustajoki P. Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene. Hum. Mol. Genet. 4, 215-222 (1995).
42. Schreiber WE, Rozon C, Fong F, Jama A. Detection of polymorphisms and mutations in the porphobilinogen deaminase gene by nonisotopic SSCP. Clin. Chem. 40, 1982-1983 (1994).
43. Nissen H, Petersen NE, Mustajoki S et al. Diagnostic strategy, genetic diagnosis and identification of new mutations in intermittent porphyria by denaturing gradient gel electrophoresis. Hum. Mutat. 9, 122-130 (1997).
44. Ong PM, Lanyon WG, Hift RJ et al. Identification of two novel mutations in the hydroxymethylbilane synthase gene in three patients from two unrelated families with acute intermittent porphyria. Hum. Hered. 48, 24-29 (1998).
45. Schreiber WE, Fong F, Nassar BA, Jamani A. Heteroduplex analysis detects frameshift and point mutations in patients with acute intermittent porphyria. Hum. Genet. 92, 161-166 (1995).
46. Tchernitchko D, Lamoril J, Puy H et al. Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis. Clin. Chim. Acta 279, 133-143 (1999).
47. Fischer J, Schwab M, Eichelbaum M, Zanger UM. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography Genet. Test. 7, 97-105 (2003).
48. Lam CW, Poon PM, Tong SF et al. Novel mutation and polymorphisms of the HMBS gene detected by denaturing HPLC. Clin. Chem. 47, 343-346 (2001).
49. Mustajoki S, Kauppinen R, Mustajoki P, Suomalainen A, Peltonen L. Steady-state transcript levels of the porphobilinogen deaminase gene in patients with acute intermittent porphyria. Genome Res. 7, 1054-1060 (1997).
50. Landers JP. Molecular diagnostics on electrophoretic microchips. Ann. Chem. 75, 2919-2927 (2003).
51. Bonk T, Humeny A, Gebert J, Sutter C, von Knebel Doeberitz M, Becker CM. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based detection of microsatellite instabilities in coding DNA sequences: a novel approach to identify DNA-mismatch repair-deficient cancer cells. Clin. Chem. 49, 552-561 (2003).
52. Law WK, Choy KW, Lam CW. Novel single nucleotide polymorphism (9678G→A) for linkage analysis of acute intermittent porphyria. Clin. Chem. 45, 308-309 (1999).
53. Mauzerall D, Granick S. The occurrence and determination of δ-aminolevulinic acid and porphobilinogen in urine. J. Biol. Chem. 219, 435-436 (1956).
54. Lim CK, Peters TJ. Urine and fecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin. Chim. Acta 139, 55-63 (1984).
55. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand. J. Clin. Lab. Invest. 60, 643-648 (2000).